SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction
|(Address of principal executive offices, including zip code)|
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02. Departure of Directors or Certain Officers
On May 17, 2021, Jon Wigginton, M.D. notified Cullinan Oncology, Inc. (the “Company”) of his resignation as Chief Medical Officer of the Company, effective May 20, 2021 (the “Effective Date”). Dr. Wigginton’s resignation was not the result of any disagreement with the Company or its Board of Directors or any matter relating to the Company’s operations, policies, or practices.
In connection with his resignation, Dr. Wigginton and the Company entered into a Consulting Agreement, dated May 20, 2021 (the “Consulting Agreement”), effective as of the Effective Date, pursuant to which Dr. Wigginton has agreed to provide advisory services as the Company and Dr. Wigginton may mutually agree to from time to time. Dr. Wigginton will also serve as Chair of the Company’s Scientific Advisory Board. As compensation for his services under the Consulting Agreement, Dr Wigginton shall be paid $31,250 per month and the equity awards held as of the Effective Date will continue to vest during the term of the Consulting Agreement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Cullinan Oncology, Inc.|
|Date: May 21, 2021||By:|
|Chief Financial Officer|